Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tigran Makunts

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Scientific Reports|February 21, 2019
Analysis of postmarketing safety data for proton-pump inhibitors reveals increased propensity for renal injury, electrolyte abnormalities, and nephrolithiasisTigran Makunts, Isaac V Cohen, Linda Awdishu, et al.
Scientific Reports|March 17, 2021
Concomitant drugs associated with increased mortality for MDMA users reported in a drug safety surveillance databaseIsaac V Cohen, Tigran Makunts, Ruben Abagyan, et al.
Frontiers in Psychiatry|February 10, 2022
Reported Cases of Serotonin Syndrome in MDMA Users in FAERS DatabaseTigran Makunts, Lisa Jerome, Ruben Abagyan, et al.
Scientific Reports|May 5, 2017
Population scale data reveals the antidepressant effects of ketamine and other therapeutics approved for non-psychiatric indicationsIsaac V Cohen, Tigran Makunts, Rabia Atayee, et al.
Scientific Reports|December 7, 2017
Publisher Correction: Population scale data reveals the antidepressant effects of ketamine and other therapeutics approved for non-psychiatric indicationsIsaac V Cohen, Tigran Makunts, Rabia Atayee, et al.
Plos One|April 19, 2018
Population scale retrospective analysis reveals distinctive antidepressant and anxiolytic effects of diclofenac, ketoprofen and naproxen in patients with painTigran Makunts, Isaac V Cohen, Kelly C Lee, et al.
Frontiers in Psychiatry|June 5, 2023
Concomitant medications associated with ischemic, hypertensive, and arrhythmic events in MDMA users in FDA adverse event reporting systemTigran Makunts, Diane Dahill, Lisa Jerome, et al.
Scientific Reports|December 22, 2021
Postmarketing safety surveillance data reveals protective effects of botulinum toxin injections against incident anxietyM Axel Wollmer, Tigran Makunts, Tillmann H C Krüger, et al.
Scientific Reports|November 6, 2020
Cardiac adverse events associated with chloroquine and hydroxychloroquine exposure in 20 years of drug safety surveillance reportsIsaac V Cohen, Tigran Makunts, Talar Moumedjian, et al.
Scientific Reports|November 23, 2019
Proton-pump inhibitor use is associated with a broad spectrum of neurological adverse events including impaired hearing, vision, and memoryTigran Makunts, Sama Alpatty, Kelly C Lee, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Scientific Reports|February 21, 2019
Analysis of postmarketing safety data for proton-pump inhibitors reveals increased propensity for renal injury, electrolyte abnormalities, and nephrolithiasisTigran Makunts, Isaac V Cohen, Linda Awdishu, et al.
Scientific Reports|March 17, 2021
Concomitant drugs associated with increased mortality for MDMA users reported in a drug safety surveillance databaseIsaac V Cohen, Tigran Makunts, Ruben Abagyan, et al.
Frontiers in Psychiatry|February 10, 2022
Reported Cases of Serotonin Syndrome in MDMA Users in FAERS DatabaseTigran Makunts, Lisa Jerome, Ruben Abagyan, et al.
Scientific Reports|May 5, 2017
Population scale data reveals the antidepressant effects of ketamine and other therapeutics approved for non-psychiatric indicationsIsaac V Cohen, Tigran Makunts, Rabia Atayee, et al.
Scientific Reports|December 7, 2017
Publisher Correction: Population scale data reveals the antidepressant effects of ketamine and other therapeutics approved for non-psychiatric indicationsIsaac V Cohen, Tigran Makunts, Rabia Atayee, et al.
Plos One|April 19, 2018
Population scale retrospective analysis reveals distinctive antidepressant and anxiolytic effects of diclofenac, ketoprofen and naproxen in patients with painTigran Makunts, Isaac V Cohen, Kelly C Lee, et al.
Frontiers in Psychiatry|June 5, 2023
Concomitant medications associated with ischemic, hypertensive, and arrhythmic events in MDMA users in FDA adverse event reporting systemTigran Makunts, Diane Dahill, Lisa Jerome, et al.
Scientific Reports|December 22, 2021
Postmarketing safety surveillance data reveals protective effects of botulinum toxin injections against incident anxietyM Axel Wollmer, Tigran Makunts, Tillmann H C Krüger, et al.
Scientific Reports|November 6, 2020
Cardiac adverse events associated with chloroquine and hydroxychloroquine exposure in 20 years of drug safety surveillance reportsIsaac V Cohen, Tigran Makunts, Talar Moumedjian, et al.
Scientific Reports|November 23, 2019
Proton-pump inhibitor use is associated with a broad spectrum of neurological adverse events including impaired hearing, vision, and memoryTigran Makunts, Sama Alpatty, Kelly C Lee, et al.
Pageof 3